Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04986748

Using QPOP to Predict Treatment for Sarcomas and Melanomas

This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.

Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Sarcoma Melanoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Connective and Soft Tissue Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

21 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Cancer Centre Singapore

Singapore, 169610

Location status: Recruiting

Location contact

Valerie Shiwen Yang, BSc, MB BChir, PhD

CONTACT

About this study

Hypothesis: Ex vivo drug testing on patient-derived models using QPOP can identify drug sensitivities and combinations which may have clinical efficacy against sarcomas and melanomas.

Specific aim 1: To derive patient models, both two- and three-dimensional, of sarcomas and melanomas

Specific aim 2: To perform ex vivo drug testing on patient models of sarcoma and melanoma using QPOP

Specific aim 3: To assess the efficacy of phenotype directed therapy using QPOP to assign treatment after progression on standard-of-care treatment in sarcoma and melanoma

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of sarcoma or melanoma
  • At least 1 tumour lesion amenable to fresh biopsy or resection
  • Signed informed consent from patient or legal representative
  • Able to comply with study-related procedures

Exclusion criteria

  • There are no specific exclusion criteria if patients meet the inclusion criteria

Treatment and study plan

Primary outcomes

  1. Percentage of patients with successful model generation for each tumour subtype.

    Time frame: 8 years.

    Patients enrolled on study will undergo resection or biopsy of fresh tumour tissue to obtain cells for the generation of models.

  2. Rates of radiological response from QPOP-directed treatment regimens.

    Time frame: 8 years.

    Complete and partial clinical response and stable disease.

  3. Survival outcomes from QPOP-directed treatment regimens.

    Time frame: 8 years.

    Overall survival, progression-free survival.

Study contacts

Contact information is provided by the study sponsor or research team.

Valerie Shiwen Yang, BSc, MB BChir, PhD

CONTACT

[email protected]

+65 6436 8088

Sponsors and collaborators

Lead sponsor

National Cancer Centre, Singapore

Other

Registry information

Official study title

Q-SAM (Using QPOP to Predict Treatment for Sarcomas and Melanomas)

Important dates

Study start
2020
Primary completion
2028
Study completion
2028
First posted
Aug 3, 2021
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.